Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
About this item
Full title
Author / Creator
McDermott, Mary M. , Martens, Christopher R. , Domanchuk, Kathryn J. , Zhang, Dongxue , Peek, Clara B. , Criqui, Michael H. , Ferrucci, Luigi , Greenland, Philip , Guralnik, Jack M. , Ho, Karen J. , Kibbe, Melina R. , Kosmac, Kate , Lloyd-Jones, Donald , Peterson, Charlotte A. , Sufit, Robert , Tian, Lu , Wohlgemuth, Stephanie , Zhao, Lihui , Zhu, Pei and Leeuwenburgh, Christiaan
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
People with lower extremity peripheral artery disease (PAD) have increased oxidative stress, impaired mitochondrial activity, and poor walking performance. NAD+ reduces oxidative stress and is an essential cofactor for mitochondrial respiration. Oral nicotinamide riboside (NR) increases bioavailability of NAD+ in humans. Among 90 people with PAD, t...
Alternative Titles
Full title
Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
Authors, Artists and Contributors
Author / Creator
Martens, Christopher R.
Domanchuk, Kathryn J.
Zhang, Dongxue
Peek, Clara B.
Criqui, Michael H.
Ferrucci, Luigi
Greenland, Philip
Guralnik, Jack M.
Ho, Karen J.
Kibbe, Melina R.
Kosmac, Kate
Lloyd-Jones, Donald
Peterson, Charlotte A.
Sufit, Robert
Tian, Lu
Wohlgemuth, Stephanie
Zhao, Lihui
Zhu, Pei
Leeuwenburgh, Christiaan
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_2c373f254eb346318d878694e2b1a44e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2c373f254eb346318d878694e2b1a44e
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-024-49092-5
